Dr. Helmut Brunar is a pharma/biotech executive with expertise in vaccines, cell-therapies and diagnostic products. Before joining as Viravaxx’ CEO, he managed supply chain activities at Johnson & Johnson’s COVID-19 vaccine program. Prior to this, he was CEO & Chairman with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA.
Head of (Pre-)Clinical Development & Diagnostics
Dr. Frank Stolz is an experienced head of pre-clinical and clinical product development with a successful history of working in biotechnology and in basic research. At Viravaxx, he is responsible for product innovation, process and analytical development. He leads Viravaxx’ preclinical vaccine development and diagnostic platforms.
As of Dec 31, 2020, Dr. Rainer Henning left Viravaxx as CEO to pursue new opportunities. He’ll be supporting the new management during the transition phase.